Virginia Retirement Systems ET AL Buys Shares of 16,400 Shattuck Labs, Inc. (NASDAQ:STTK)

Virginia Retirement Systems ET AL purchased a new stake in Shattuck Labs, Inc. (NASDAQ:STTKGet Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 16,400 shares of the company’s stock, valued at approximately $140,000.

Several other large investors have also recently made changes to their positions in STTK. Investment Management of Virginia LLC increased its position in Shattuck Labs by 395.6% in the 4th quarter. Investment Management of Virginia LLC now owns 181,656 shares of the company’s stock valued at $1,545,000 after acquiring an additional 145,000 shares during the period. Victory Capital Management Inc. increased its holdings in shares of Shattuck Labs by 64.1% during the third quarter. Victory Capital Management Inc. now owns 148,140 shares of the company’s stock valued at $3,019,000 after purchasing an additional 57,840 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Shattuck Labs by 96.1% during the third quarter. Ensign Peak Advisors Inc now owns 58,822 shares of the company’s stock valued at $1,199,000 after purchasing an additional 28,822 shares in the last quarter. EcoR1 Capital LLC lifted its holdings in Shattuck Labs by 11.8% in the third quarter. EcoR1 Capital LLC now owns 3,709,072 shares of the company’s stock worth $75,591,000 after purchasing an additional 390,662 shares during the period. Finally, Prosight Management LP bought a new position in Shattuck Labs in the 3rd quarter valued at about $3,449,000. Institutional investors own 66.62% of the company’s stock.

Shares of Shattuck Labs stock opened at $3.90 on Friday. Shattuck Labs, Inc. has a 52 week low of $3.35 and a 52 week high of $38.90. The stock has a market cap of $164.76 million, a PE ratio of -3.64 and a beta of 3.30. The company’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $8.69.

Shattuck Labs (NASDAQ:STTKGet Rating) last announced its quarterly earnings data on Tuesday, March 15th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.61. The business had revenue of $30.08 million during the quarter. Equities research analysts anticipate that Shattuck Labs, Inc. will post -2.25 EPS for the current fiscal year.

A number of analysts have commented on STTK shares. Needham & Company LLC dropped their price target on shares of Shattuck Labs from $46.00 to $31.00 and set a “buy” rating on the stock in a research report on Wednesday, March 16th. Zacks Investment Research upgraded Shattuck Labs from a “sell” rating to a “hold” rating in a research report on Wednesday, January 12th.

About Shattuck Labs (Get Rating)

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Featured Articles

Want to see what other hedge funds are holding STTK? Visit to get the latest 13F filings and insider trades for Shattuck Labs, Inc. (NASDAQ:STTKGet Rating).

Institutional Ownership by Quarter for Shattuck Labs (NASDAQ:STTK)

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with's FREE daily email newsletter.